- Major pharmaceutical companies, including Pfizer, Amgen, Eli Lilly, and Novo Nordisk, are leading the market in next-generation GLP-1 drugs for weight loss and diabetes.
- Eli Lilly and Novo Nordisk both launched oral GLP-1 medications this year, marking a major competitive development in the market.
- Lilly and Novo Nordisk are competing in the weight loss drug market, with Lilly expanding its US market coverage.
- Eli Lilly and Novo Nordisk have both developed anti-obesity drugs, intensifying competition in the weight loss market.
Eli Lilly raised Zepbound prices in the U.K. and plans to follow price hikes across Europe, while Novo Nordisk received a drug price reduction letter amid Trump administration pressure.
5 reports, 5 independent
Updated Jul 29
Gone quiet
Reached 4 outlets in its first 24 hours
- Reports
- 5
- Developments
- 5
- Repetition
- 40%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Eli Lilly raised Zepbound prices in the U.K. and plans to follow price hikes across Europe, while Novo Nordisk received a drug price reduction letter amid Trump administration pressure.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- The FDA has ruled on copycat drugs produced in China, while Novo Nordisk navigates price reduction demands from Trump and leadership changes.Sub-event
- Lilly and Novo Nordisk are competing in the weight loss drug market, with Lilly introducing Mounjaro via the NHS and facing US pricing pressure from Trump.Sub-event
Lilly's international price hikes and competitive market pressures from the Trump administration.1 source
Lilly hikes Mounjaro prices in the UK amid competition with Novo Nordisk and Trump's push for lower US drug costs.1 source
Market lead shifts to Eli Lilly; FDA allows copycats; leadership changes at Novo Nordisk.1 source
Keep exploring
Part of
Eli Lilly and Novo Nordisk have both developed anti-obesity drugs, intensifying competition in the weight loss market.Also in this story
- Novo Nordisk strengthens its R&D pipeline in the fields of obesity and diabetes.
- Eli Lilly's tirzepatide proved more effective than Novo Nordisk's semaglutide in the obesity drug market.
The entities involved
-
Eli Lilly and Company
American pharmaceutical company
-
Novo Nordisk
Danish pharmaceutical company
Related events
- Eli Lilly captured market share from Novo Nordisk in the weight loss drug sector.
- Eli Lilly and Novo Nordisk products are currently awaiting necessary approval from the Food and Drug Administration.
- Novo Nordisk, Merck, and Eli Lilly are noted as large pharmaceutical rivals with recent drug approvals and market presence in the US.
- Novo Nordisk operates in Europe, North America, the Middle East, and mainland China, while MarketBeat covers both Novo Nordisk and Eli Lilly.
- Speculation links Donald Trump to issues regarding drug access.
Coverage
Newest first; wire copies grouped- newsweek.com
- Motley FoolWhy Novo Nordisk Flew Almost 3% Higher on Friday The company's leading product looked more attractive following price hikes by a competitor. Eli Lilly's Zepbound will become more expensive in the U.K
- Pharmaceutical TechnologyUK pharmacist says Eli Lilly’s Mounjaro price hike a “shock” Eli Lilly will increase the UK list price of its blockbuster drug Mounjaro (tirzepatide) amid pressure from US President Donald Trump for
- CNN BusinessEli Lilly hikes Mounjaro prices in the UK to make weight-loss drug cheaper in the US Eli Lilly will significantly increase the price of its weight-loss drug Mounjaro in the United Kingdom in a bid to
- Yahoo FinanceCash pay is 'going to constitute a major part of the Wegovy business': Novo Nordisk CFO Novo Nordisk (NVO) reported an earnings miss Wednesday, sending its stock down 4% in early trading, pressuring